<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8189568</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">34113841</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">8189568</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pii">S2590-1125(20)30019-0</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.prdoa.2020.100051</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">100051</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical data (N = 35).</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Demographic and clinical data (N = 35).</p></caption><alt-text id="al0010">Table 1</alt-text><table frame="hsides" rules="groups"><tbody><tr><td>Age (yr)</td><td>64.3 ± 8.7</td></tr><tr><td>Gender</td><td>10 F, 25 M</td></tr><tr><td>Handedness</td><td>33 R, 2 L</td></tr><tr><td>Onset side</td><td>22 R, 13 L</td></tr><tr><td>Disease duration (yr)</td><td>6.2 ± 3.8</td></tr><tr><td>H &amp; Y</td><td>2.0 ± 0.0</td></tr><tr><td>MDS-UPDRS</td><td/></tr><tr><td> Part I</td><td>8.5 ± 4.1</td></tr><tr><td> Part II</td><td>11.2 ± 5.4</td></tr><tr><td> Part III</td><td>27.7 ± 7.3</td></tr><tr><td> Part IV</td><td>1.9 ± 2.6</td></tr><tr><td> Total</td><td>49.4 ± 14.3</td></tr><tr><td>LEDD (mg)</td><td>523.8 ± 335.3</td></tr><tr><td>MoCA</td><td>27.9 ± 1.9</td></tr><tr><td>STAI-T</td><td>34.5 ± 10.5</td></tr><tr><td>BDI-II</td><td>7.6 ± 7.2</td></tr><tr><td>Apathy</td><td>8.7 ± 5.2</td></tr><tr><td>PDSI</td><td>17.5 ± 11.7</td></tr><tr><td>PFS</td><td>2.3 ± 0.9</td></tr><tr><td>SRS</td><td>30.8 ± 4.6</td></tr><tr><td>NGSES</td><td>4.1 ± 0.6</td></tr></tbody></table><table-wrap-foot><fn><p>The age range was 45–79 years. Disease duration was defined as the time since the first motor symptom was noticeable to the subject. BDI-II: Beck Depression Inventory-II, H &amp; Y: Hoehn &amp; Yahr, LEDD: Levodopa Equivalent Daily Dose, MDS-UPDRS: Movement Disorders Society Unified Parkinson's Disease Rating Scale, MoCA: Montreal Cognitive Assessment battery, NGSES: New General Self-Efficacy Scale, PDSI: Parkinson's Disease Summary Index based on the PD Quality of Life-39 questionnaire, PFS: Parkinson's Fatigue Scale mean score, SRS: Self-Regulation Scale, STAI-T: Spielberger Trait Anxiety Inventory, F/M: Female/Male, L/R: Left/Right.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical data (N = 35).</div>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td>Age (yr)</td><td>64.3 ± 8.7</td></tr><tr><td>Gender</td><td>10 F, 25 M</td></tr><tr><td>Handedness</td><td>33 R, 2 L</td></tr><tr><td>Onset side</td><td>22 R, 13 L</td></tr><tr><td>Disease duration (yr)</td><td>6.2 ± 3.8</td></tr><tr><td>H &amp; Y</td><td>2.0 ± 0.0</td></tr><tr><td>MDS-UPDRS</td><td/></tr><tr><td> Part I</td><td>8.5 ± 4.1</td></tr><tr><td> Part II</td><td>11.2 ± 5.4</td></tr><tr><td> Part III</td><td>27.7 ± 7.3</td></tr><tr><td> Part IV</td><td>1.9 ± 2.6</td></tr><tr><td> Total</td><td>49.4 ± 14.3</td></tr><tr><td>LEDD (mg)</td><td>523.8 ± 335.3</td></tr><tr><td>MoCA</td><td>27.9 ± 1.9</td></tr><tr><td>STAI-T</td><td>34.5 ± 10.5</td></tr><tr><td>BDI-II</td><td>7.6 ± 7.2</td></tr><tr><td>Apathy</td><td>8.7 ± 5.2</td></tr><tr><td>PDSI</td><td>17.5 ± 11.7</td></tr><tr><td>PFS</td><td>2.3 ± 0.9</td></tr><tr><td>SRS</td><td>30.8 ± 4.6</td></tr><tr><td>NGSES</td><td>4.1 ± 0.6</td></tr></tbody></table></div>The age range was 45–79 years. Disease duration was defined as the time since the first motor symptom was noticeable to the subject. BDI-II: Beck Depression Inventory-II, H &amp; Y: Hoehn &amp; Yahr, LEDD: Levodopa Equivalent Daily Dose, MDS-UPDRS: Movement Disorders Society Unified Parkinson's Disease Rating Scale, MoCA: Montreal Cognitive Assessment battery, NGSES: New General Self-Efficacy Scale, PDSI: Parkinson's Disease Summary Index based on the PD Quality of Life-39 questionnaire, PFS: Parkinson's Fatigue Scale mean score, SRS: Self-Regulation Scale, STAI-T: Spielberger Trait Anxiety Inventory, F/M: Female/Male, L/R: Left/Right.</transformed-table></extracted-table><extracted-table><table-id>t0010</table-id><table-label>Table 2</table-label><table-caption>Stepwise linear regression results.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0010"><label>Table 2</label><caption><p>Stepwise linear regression results.</p></caption><alt-text id="al0015">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>t</th><th>p</th></tr></thead><tbody><tr><td colspan="3">NGSES scores:</td></tr><tr><td>MDS-UPDRS total</td><td align="char">−3.75</td><td align="char">0.001</td></tr><tr><td>Apathy</td><td align="char">−4.67</td><td align="char">0.000</td></tr><tr><td colspan="3">  </td></tr><tr><td colspan="3">SRS scores:</td></tr><tr><td>MDS-UPDRS total</td><td align="char">−2.99</td><td align="char">0.005</td></tr><tr><td>Apathy</td><td align="char">−4.49</td><td align="char">0.000</td></tr></tbody></table><table-wrap-foot><fn><p>Both NGSES and SRS scores showed significant negative correlations with the MDS-UPDRS total (beta = −0.14 and −0.12, respectively) and apathy (beta = −0.49 and −0.49, respectively) scores. The beta coefficients are unstandardized. MDS-UPDRS: Movement Disorders Society Unified Parkinson's Disease Rating Scale, NGSES: New General Self-Efficacy Scale, SRS: Self-Regulation Scale.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Stepwise linear regression results.</div>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>t</th><th>p</th></tr></thead><tbody><tr><td colspan="3">NGSES scores:</td></tr><tr><td>MDS-UPDRS total</td><td align="char">−3.75</td><td align="char">0.001</td></tr><tr><td>Apathy</td><td align="char">−4.67</td><td align="char">0.000</td></tr><tr><td colspan="3">  </td></tr><tr><td colspan="3">SRS scores:</td></tr><tr><td>MDS-UPDRS total</td><td align="char">−2.99</td><td align="char">0.005</td></tr><tr><td>Apathy</td><td align="char">−4.49</td><td align="char">0.000</td></tr></tbody></table></div>Both NGSES and SRS scores showed significant negative correlations with the MDS-UPDRS total (beta = −0.14 and −0.12, respectively) and apathy (beta = −0.49 and −0.49, respectively) scores. The beta coefficients are unstandardized. MDS-UPDRS: Movement Disorders Society Unified Parkinson's Disease Rating Scale, NGSES: New General Self-Efficacy Scale, SRS: Self-Regulation Scale.</transformed-table></extracted-table><extracted-table><table-id>t0015</table-id><table-label>Table 3</table-label><table-caption>Correlations of SRS and NGSES scores with nodal pairwise functional connectivity.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0015"><label>Table 3</label><caption><p>Correlations of SRS and NGSES scores with nodal pairwise functional connectivity.</p></caption><alt-text id="al0020">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>t</th><th>p</th></tr></thead><tbody><tr><td colspan="3">SRS</td></tr><tr><td>Positive correlation:</td><td/><td/></tr><tr><td>dACC (SN) – rAI (SN)</td><td align="char">3.19</td><td align="char">0.049</td></tr><tr><td>Negative correlation:</td><td/><td/></tr><tr><td>dACC (SN) – lLatPar (DMN)</td><td align="char">−3.69</td><td align="char">0.025</td></tr><tr><td colspan="3">  </td></tr><tr><td colspan="3">NGSES</td></tr><tr><td>Positive correlation:</td><td/><td/></tr><tr><td>dACC (SN) – rAI (SN)</td><td align="char">3.53</td><td align="char">0.040</td></tr></tbody></table><table-wrap-foot><fn><p>dACC: Dorsal anterior cingulate cortex, DMN: Default mode network, lLatPar: Left lateral parietal, NGSES: New general self-efficacy scale, rAI: Right anterior insula, SN: Salience network, SRS: Self-regulation scale. p values are FDR-corrected.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Correlations of SRS and NGSES scores with nodal pairwise functional connectivity.</div>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>t</th><th>p</th></tr></thead><tbody><tr><td colspan="3">SRS</td></tr><tr><td>Positive correlation:</td><td/><td/></tr><tr><td>dACC (SN) – rAI (SN)</td><td align="char">3.19</td><td align="char">0.049</td></tr><tr><td>Negative correlation:</td><td/><td/></tr><tr><td>dACC (SN) – lLatPar (DMN)</td><td align="char">−3.69</td><td align="char">0.025</td></tr><tr><td colspan="3">  </td></tr><tr><td colspan="3">NGSES</td></tr><tr><td>Positive correlation:</td><td/><td/></tr><tr><td>dACC (SN) – rAI (SN)</td><td align="char">3.53</td><td align="char">0.040</td></tr></tbody></table></div>dACC: Dorsal anterior cingulate cortex, DMN: Default mode network, lLatPar: Left lateral parietal, NGSES: New general self-efficacy scale, rAI: Right anterior insula, SN: Salience network, SRS: Self-regulation scale. p values are FDR-corrected.</transformed-table></extracted-table></extracted-tables-set>